FAM
ESPR

Formidable Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Formidable Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-100
Closed -$1K – 241
2016
Q1 		$1K Hold
100
– – ﹤0.01% 477
2015
Q4 		$2K Hold
100
– – ﹤0.01% 510
2015
Q3 		$2K Hold
100
– – ﹤0.01% 567
2015
Q2 		$8K Hold
100
– – 0.01% 386
2015
Q1 		$11K Buy
+100
New +$6.45K 0.01% 335

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Formidable Asset Management's ESPR Position: Q2 2016 in Review

Formidable Asset Management sold out of Esperion Therapeutics (ESPR) in Q2 2016, closing a stake of 100 shares — an estimated $1K sold.

Formidable Asset Management first reported a position in ESPR in Q1 2015 and held it in 5 quarters. The position peaked at $11K in Q1 2015. 102 funds tracked by Wall St. Rank hold ESPR as of Q2 2016.

  • Formidable Asset Management reported no remaining Esperion Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Formidable Asset Management sold 100 Esperion Therapeutics shares in Q2 2016, an estimated $1K.
  • Formidable Asset Management first reported a position in Esperion Therapeutics in Q1 2015 and held it in 5 quarters.
  • Formidable Asset Management's Esperion Therapeutics position peaked at $11K in Q1 2015.
  • 102 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2016.

Based on Formidable Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.